Hydra Stop LLC
Total Consideration
$292.1M
Purchase-Price Allocation
Goodwill
$169.2M
3 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 19.00% | 19.00% | 19.00% | 23.50% | 25.00% | 25.00% |
| State & Local Income Taxes | — | — | — | — | — | — |
| Foreign Rate Differential | -3.90% | -5.10% | -7.60% | -13.20% | -11.50% | — |
| Other Adjustments | — | — | — | — | — | 0.20% |
| SBC (Nondeductible) | — | — | — | — | — | — |
| Nondeductible Expenses | — | — | — | — | — | — |
| Valuation Allowance Change | 1.30% | -0.20% | 1.00% | 2.20% | 2.00% | — |
| Tax Law Change | 0.00% | — | — | — | — | — |
| Qualified Production Activities (Legacy DPAD) | — | — | — | — | — | — |
| Effective Tax Rate | 17.40% | 11.30% | 12.20% | -0.60% | 13.00% | 14.10% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $75.0M | $70.8M | $67.4M | −$4.0M | $93.3M | $107.0M |
| Income Taxes Paid (Cash) | — | — | — | — | — | $86.9M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$292.1M
Purchase-Price Allocation
Goodwill
$169.2M
Total Consideration
$116.0M
Purchase-Price Allocation
Goodwill
$56.6M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Severance And Related Costs | Employee Severance | +$27M | — | — |
| Other Restructuring | Other | +$7M | — | — |
| Asset Impairment And Write Offs | Asset Impairment / Write-Down | +$2M | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).